TFL Gallery / t-ae-incidence
AET03 · Table
Incidence of Treatment Emergent Adverse Events by Treatment Group
The reference report's Table 14-5.01: subjects, percentages and event counts per system organ class and preferred term, with Fisher's exact test of placebo against each active arm.
- Slug
- t-ae-incidence
- Regulatory ID
- AET03
- Type
- Table
- E3 position
- §14.3.1
- Status
- evidenced
- Current iteration
- v007
- Evidence
- 25/25 passing
- Requirements
- DSP-AEI-001 DSP-AEI-002 DSP-AEI-003 DSP-AEI-004 DSP-ALL-001 DSP-ALL-002 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 DSP-REF-001 DSP-REF-002 DSP-REF-003 DSP-REF-004 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
- Used in
- Clinical Study Report Table 14.3.1.4
- Post-Text Display Package Table 14.3.1.4
- Abbreviated Clinical Study Report (ICH E3) Table 14.3.1.4
- Study model
- Safety Analysis Set SAFFL · grouped by TRT01A
- Specification
- 7 iterations
- Environment
- R 4.3.3 Darwin 23.6.0
- Bound by
- No text block binds it
- Values
- No value is sourced from it
- adsl254 rows · b022f78
- adae1191 rows · 4ffe4e4
- analysis.yamlwhat to compute
- display.yamlhow to show it
- custom.Rthe display's own method
- study modelSafety Analysis Set
- prepare_data()regenerate('t-ae-incidence')
- build_ard()one row per statistic
- render_display()every variant
- render_rtf()the same cells
- ard.jsonv007 · 4826 rows · 091de51
- table.htmlthe rendered display
- table.rtfsha256 6946cff
- table-in-text.rtfsha256 93fb296
- manifest.jsonwho, why, every hash
Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.
| Incidence of Treatment Emergent Adverse Events by Treatment Group | |||||
| Study CDISCPILOT01 — Safety Analysis Set | |||||
| Placebo (N=86) | Xanomeline Low Dose (N=84) | Xanomeline High Dose (N=84) | Placebo vs. Low Dose | Placebo vs. High Dose | |
|---|---|---|---|---|---|
| ANY BODY SYSTEM | |||||
| CARDIAC DISORDERS | |||||
| SINUS BRADYCARDIA | |||||
| MYOCARDIAL INFARCTION | |||||
| ATRIAL FIBRILLATION | |||||
| ATRIAL FLUTTER | |||||
| CARDIAC DISORDER | |||||
| SUPRAVENTRICULAR EXTRASYSTOLES | |||||
| VENTRICULAR EXTRASYSTOLES | |||||
| ATRIAL HYPERTROPHY | |||||
| ATRIOVENTRICULAR BLOCK FIRST DEGREE | |||||
| ATRIOVENTRICULAR BLOCK SECOND DEGREE | |||||
| BRADYCARDIA | |||||
| BUNDLE BRANCH BLOCK LEFT | |||||
| BUNDLE BRANCH BLOCK RIGHT | |||||
| CARDIAC FAILURE CONGESTIVE | |||||
| PALPITATIONS | |||||
| SINUS ARRHYTHMIA | |||||
| SUPRAVENTRICULAR TACHYCARDIA | |||||
| TACHYCARDIA | |||||
| VENTRICULAR HYPERTROPHY | |||||
| WOLFF-PARKINSON-WHITE SYNDROME | |||||
| CONGENITAL, FAMILIAL AND GENETIC DISORDERS | |||||
| VENTRICULAR SEPTAL DEFECT | |||||
| EAR AND LABYRINTH DISORDERS | |||||
| VERTIGO | |||||
| CERUMEN IMPACTION | |||||
| EAR PAIN | |||||
| EYE DISORDERS | |||||
| VISION BLURRED | |||||
| CONJUNCTIVAL HAEMORRHAGE | |||||
| CONJUNCTIVITIS | |||||
| EYE ALLERGY | |||||
| EYE PRURITUS | |||||
| EYE SWELLING | |||||
| GASTROINTESTINAL DISORDERS | |||||
| VOMITING | |||||
| NAUSEA | |||||
| DIARRHOEA | |||||
| SALIVARY HYPERSECRETION | |||||
| ABDOMINAL DISCOMFORT | |||||
| ABDOMINAL PAIN | |||||
| GASTROINTESTINAL HAEMORRHAGE | |||||
| STOMACH DISCOMFORT | |||||
| CONSTIPATION | |||||
| DYSPEPSIA | |||||
| DYSPHAGIA | |||||
| FLATULENCE | |||||
| GASTROOESOPHAGEAL REFLUX DISEASE | |||||
| GLOSSITIS | |||||
| HIATUS HERNIA | |||||
| RECTAL HAEMORRHAGE | |||||
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | |||||
| APPLICATION SITE PRURITUS | |||||
| APPLICATION SITE ERYTHEMA | |||||
| APPLICATION SITE IRRITATION | |||||
| APPLICATION SITE DERMATITIS | |||||
| APPLICATION SITE VESICLES | |||||
| FATIGUE | |||||
| APPLICATION SITE PAIN | |||||
| APPLICATION SITE PERSPIRATION | |||||
| APPLICATION SITE SWELLING | |||||
| CHEST DISCOMFORT | |||||
| CHEST PAIN | |||||
| MALAISE | |||||
| OEDEMA PERIPHERAL | |||||
| APPLICATION SITE DISCHARGE | |||||
| APPLICATION SITE REACTION | |||||
| APPLICATION SITE URTICARIA | |||||
| ASTHENIA | |||||
| CHILLS | |||||
| FEELING ABNORMAL | |||||
| FEELING COLD | |||||
| PAIN | |||||
| PYREXIA | |||||
| APPLICATION SITE BLEEDING | |||||
| APPLICATION SITE DESQUAMATION | |||||
| APPLICATION SITE DISCOLOURATION | |||||
| APPLICATION SITE INDURATION | |||||
| APPLICATION SITE WARMTH | |||||
| INFLAMMATION | |||||
| OEDEMA | |||||
| SECRETION DISCHARGE | |||||
| SUDDEN DEATH | |||||
| SWELLING | |||||
| ULCER | |||||
| HEPATOBILIARY DISORDERS | |||||
| HYPERBILIRUBINAEMIA | |||||
| IMMUNE SYSTEM DISORDERS | |||||
| HYPERSENSITIVITY | |||||
| INFECTIONS AND INFESTATIONS | |||||
| NASOPHARYNGITIS | |||||
| UPPER RESPIRATORY TRACT INFECTION | |||||
| CYSTITIS | |||||
| HORDEOLUM | |||||
| INFLUENZA | |||||
| LOWER RESPIRATORY TRACT INFECTION | |||||
| RHINITIS | |||||
| URINARY TRACT INFECTION | |||||
| BRONCHITIS | |||||
| CELLULITIS | |||||
| CERVICITIS | |||||
| EAR INFECTION | |||||
| GASTROENTERITIS VIRAL | |||||
| LOCALISED INFECTION | |||||
| PNEUMONIA | |||||
| VAGINAL MYCOSIS | |||||
| VIRAL INFECTION | |||||
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS | |||||
| CONTUSION | |||||
| HIP FRACTURE | |||||
| EXCORIATION | |||||
| FACIAL BONES FRACTURE | |||||
| FALL | |||||
| JOINT DISLOCATION | |||||
| SKIN LACERATION | |||||
| WOUND | |||||
| INVESTIGATIONS | |||||
| BIOPSY | |||||
| BIOPSY PROSTATE | |||||
| BLOOD CHOLESTEROL INCREASED | |||||
| BLOOD GLUCOSE INCREASED | |||||
| ELECTROCARDIOGRAM T WAVE INVERSION | |||||
| WEIGHT DECREASED | |||||
| BLOOD ALKALINE PHOSPHATASE INCREASED | |||||
| BLOOD CREATINE PHOSPHOKINASE INCREASED | |||||
| BLOOD URINE PRESENT | |||||
| BODY TEMPERATURE INCREASED | |||||
| CYSTOSCOPY | |||||
| ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | |||||
| ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED | |||||
| HEART RATE INCREASED | |||||
| HEART RATE IRREGULAR | |||||
| NASAL MUCOSA BIOPSY | |||||
| METABOLISM AND NUTRITION DISORDERS | |||||
| DECREASED APPETITE | |||||
| INCREASED APPETITE | |||||
| DEHYDRATION | |||||
| DIABETES MELLITUS | |||||
| FOOD CRAVING | |||||
| HYPONATRAEMIA | |||||
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | |||||
| BACK PAIN | |||||
| ARTHRALGIA | |||||
| ARTHRITIS | |||||
| FLANK PAIN | |||||
| MUSCLE SPASMS | |||||
| MYALGIA | |||||
| MUSCULAR WEAKNESS | |||||
| PAIN IN EXTREMITY | |||||
| SHOULDER PAIN | |||||
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) | |||||
| PROSTATE CANCER | |||||
| COLON CANCER | |||||
| MALIGNANT FIBROUS HISTIOCYTOMA | |||||
| NERVOUS SYSTEM DISORDERS | |||||
| DIZZINESS | |||||
| HEADACHE | |||||
| SYNCOPE | |||||
| BURNING SENSATION | |||||
| AMNESIA | |||||
| COGNITIVE DISORDER | |||||
| HYPERSOMNIA | |||||
| LETHARGY | |||||
| PARAESTHESIA | |||||
| PAROSMIA | |||||
| PARTIAL SEIZURES WITH SECONDARY GENERALISATION | |||||
| SOMNOLENCE | |||||
| SYNCOPE VASOVAGAL | |||||
| TRANSIENT ISCHAEMIC ATTACK | |||||
| BALANCE DISORDER | |||||
| COMPLEX PARTIAL SEIZURES | |||||
| COORDINATION ABNORMAL | |||||
| HEMIANOPIA HOMONYMOUS | |||||
| PARAESTHESIA ORAL | |||||
| PARKINSON'S DISEASE | |||||
| PSYCHOMOTOR HYPERACTIVITY | |||||
| STUPOR | |||||
| PSYCHIATRIC DISORDERS | |||||
| INSOMNIA | |||||
| AGITATION | |||||
| CONFUSIONAL STATE | |||||
| DELIRIUM | |||||
| DELUSION | |||||
| HALLUCINATION | |||||
| HALLUCINATION, VISUAL | |||||
| LIBIDO DECREASED | |||||
| LISTLESS | |||||
| NIGHTMARE | |||||
| ANXIETY | |||||
| COMPLETED SUICIDE | |||||
| DEPRESSED MOOD | |||||
| DISORIENTATION | |||||
| IRRITABILITY | |||||
| RESTLESSNESS | |||||
| RENAL AND URINARY DISORDERS | |||||
| CALCULUS URETHRAL | |||||
| MICTURITION URGENCY | |||||
| NEPHROLITHIASIS | |||||
| DYSURIA | |||||
| INCONTINENCE | |||||
| POLLAKIURIA | |||||
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS | |||||
| BENIGN PROSTATIC HYPERPLASIA | |||||
| PELVIC PAIN | |||||
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | |||||
| COUGH | |||||
| NASAL CONGESTION | |||||
| EPISTAXIS | |||||
| ALLERGIC GRANULOMATOUS ANGIITIS | |||||
| DYSPNOEA | |||||
| PHARYNGEAL ERYTHEMA | |||||
| PHARYNGOLARYNGEAL PAIN | |||||
| PRODUCTIVE COUGH | |||||
| RESPIRATORY TRACT CONGESTION | |||||
| RHINORRHOEA | |||||
| DYSPHONIA | |||||
| EMPHYSEMA | |||||
| HAEMOPTYSIS | |||||
| POSTNASAL DRIP | |||||
| RALES | |||||
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS | |||||
| PRURITUS | |||||
| ERYTHEMA | |||||
| RASH | |||||
| HYPERHIDROSIS | |||||
| SKIN IRRITATION | |||||
| RASH PRURITIC | |||||
| ACTINIC KERATOSIS | |||||
| BLISTER | |||||
| PRURITUS GENERALISED | |||||
| RASH MACULO-PAPULAR | |||||
| SKIN ODOUR ABNORMAL | |||||
| URTICARIA | |||||
| ALOPECIA | |||||
| COLD SWEAT | |||||
| DERMATITIS CONTACT | |||||
| DRUG ERUPTION | |||||
| RASH ERYTHEMATOUS | |||||
| SKIN EXFOLIATION | |||||
| SKIN ULCER | |||||
| SOCIAL CIRCUMSTANCES | |||||
| ALCOHOL USE | |||||
| SURGICAL AND MEDICAL PROCEDURES | |||||
| ACROCHORDON EXCISION | |||||
| SKIN LESION EXCISION | |||||
| CATARACT OPERATION | |||||
| EYE LASER SURGERY | |||||
| VASCULAR DISORDERS | |||||
| WOUND HAEMORRHAGE | |||||
| HOT FLUSH | |||||
| HYPERTENSION | |||||
| HYPOTENSION | |||||
| ORTHOSTATIC HYPOTENSION | |||||
| Treatment-emergent events are those flagged TRTEMFL = 'Y' in the study's ADAE: events that start on or after the start of treatment, as the reference report (Table 14-5.01) defines them. Adverse events are coded using MedDRA. | |||||
| Subjects are counted once per system organ class and once per preferred term; percentages are based on the number of subjects in the safety population within each treatment group. The bracketed figure is the total number of times an event was recorded. | |||||
| P-values are Fisher's exact test comparing placebo with each active treatment group on the number of subjects with the event. An asterisk is appended to p-values below 0.15, as in the reference report; a p-value that rounds to 1 prints as >0.99; where neither arm has a subject with the event there is no test and the cell is blank. | |||||
| System organ classes are in alphabetical order; preferred terms within a class are in descending order of high-dose subjects, then alphabetical — the order the reference report prints. | |||||
| Four of the 227 p-values the reference report prints differ from this display at the third decimal, each by one thousandth: vomiting (placebo vs high dose, 0.208 here, 0.209 there), salivary hypersecretion (0.057 here, 0.058 there), application site erythema (0.002 here, 0.003 there) and syncope (placebo vs low dose, 0.057 here, 0.058 there). The subject counts agree; R's exact two-sided test gives 0.2085, 0.0575, 0.0025 and 0.0575, and the 2006 program rounded each up. They are recorded and tracked in quality/data/reference-report-agreement.json. | |||||
| Source: adae, adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01. | |||||
| open.csr display t-ae-incidence (post_text variant); generated from the committed ARD. | |||||
Rendered from outputs/t-ae-incidence/v007/table.html.
| analysis | group1 | group1_level | group2 | group2_level | variable | variable_level | context | stat_name | stat_label | warning | error | stat |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| any | TRT01A | Placebo | — | — | ANY | — | subject_count | n | n | — | — | 65 |
| any | TRT01A | Placebo | — | — | ANY | — | subject_count | N | N | — | — | 86 |
| any | TRT01A | Placebo | — | — | ANY | — | subject_count | p | % | — | — | 0.755813953488372 |
| any | TRT01A | Placebo | — | — | ANY | — | subject_count | events | Events | — | — | 281 |
| any | TRT01A | Placebo | — | — | ANY | — | subject_count | sig | Placebo comparison p < 0.15 | — | — | |
| any | TRT01A | Xanomeline Low Dose | — | — | ANY | — | subject_count | n | n | — | — | 77 |
| any | TRT01A | Xanomeline Low Dose | — | — | ANY | — | subject_count | N | N | — | — | 84 |
| any | TRT01A | Xanomeline Low Dose | — | — | ANY | — | subject_count | p | % | — | — | 0.916666666666667 |
| any | TRT01A | Xanomeline Low Dose | — | — | ANY | — | subject_count | events | Events | — | — | 412 |
| any | TRT01A | Xanomeline Low Dose | — | — | ANY | — | subject_count | sig | Placebo comparison p < 0.15 | — | — | * |
| any | TRT01A | Xanomeline High Dose | — | — | ANY | — | subject_count | n | n | — | — | 76 |
| any | TRT01A | Xanomeline High Dose | — | — | ANY | — | subject_count | N | N | — | — | 84 |
| any | TRT01A | Xanomeline High Dose | — | — | ANY | — | subject_count | p | % | — | — | 0.904761904761905 |
| any | TRT01A | Xanomeline High Dose | — | — | ANY | — | subject_count | events | Events | — | — | 433 |
| any | TRT01A | Xanomeline High Dose | — | — | ANY | — | subject_count | sig | Placebo comparison p < 0.15 | — | — | * |
| any | statistic | Placebo vs. Low Dose | — | — | ANY | — | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.00653312936477891 |
| any | statistic | Placebo vs. Low Dose | — | — | ANY | — | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.007* |
| any | statistic | Placebo vs. High Dose | — | — | ANY | — | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.0136376915028284 |
| any | statistic | Placebo vs. High Dose | — | — | ANY | — | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.014* |
| by_soc_pt | TRT01A | Placebo | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | n | n | — | — | 12 |
| by_soc_pt | TRT01A | Placebo | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | p | % | — | — | 0.13953488372093 |
| by_soc_pt | TRT01A | Placebo | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | events | Events | — | — | 26 |
| by_soc_pt | TRT01A | Placebo | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | n | n | — | — | 13 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | p | % | — | — | 0.154761904761905 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | events | Events | — | — | 30 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | n | n | — | — | 15 |
| by_soc_pt | TRT01A | Xanomeline High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | p | % | — | — | 0.178571428571429 |
| by_soc_pt | TRT01A | Xanomeline High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | events | Events | — | — | 30 |
| by_soc_pt | TRT01A | Xanomeline High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.830838674053783 |
| by_soc_pt | statistic | Placebo vs. Low Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.831 |
| by_soc_pt | statistic | Placebo vs. High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.533664723024524 |
| by_soc_pt | statistic | Placebo vs. High Dose | — | — | AEBODSYS | CARDIAC DISORDERS | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.534 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | p | % | — | — | 0.0119047619047619 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | n | n | — | — | 3 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | p | % | — | — | 0.0357142857142857 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | events | Events | — | — | 5 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.364667115473196 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FIBRILLATION | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.365 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | p | % | — | — | 0.0119047619047619 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | p | % | — | — | 0.0119047619047619 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | events | Events | — | — | 2 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.494117647058824 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.494 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.494117647058824 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL FLUTTER | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.494 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | events | Events | — | — | 2 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIAL HYPERTROPHY | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | p | % | — | — | 0.0119047619047619 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK FIRST DEGREE | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | ATRIOVENTRICULAR BLOCK SECOND DEGREE | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | events | Events | — | — | 4 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BRADYCARDIA | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK LEFT | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | events | Events | — | — | 2 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | p | % | — | — | 0.0119047619047619 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | BUNDLE BRANCH BLOCK RIGHT | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | p | % | — | — | 0.0119047619047619 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hypothesis_test | p_value | Fisher's exact p-value | — | — | — |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.494117647058824 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC DISORDER | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.494 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | n | n | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | p | % | — | — | 0.0116279069767442 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | events | Events | — | — | 1 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | p | % | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | events | Events | — | — | 0 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | CARDIAC FAILURE CONGESTIVE | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | n | n | — | — | 4 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | p | % | — | — | 0.0465116279069767 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | events | Events | — | — | 4 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | n | n | — | — | 2 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | p | % | — | — | 0.0238095238095238 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | events | Events | — | — | 4 |
| by_soc_pt | TRT01A | Xanomeline Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | n | n | — | — | 4 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | N | N | — | — | 84 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | p | % | — | — | 0.0476190476190476 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | events | Events | — | — | 8 |
| by_soc_pt | TRT01A | Xanomeline High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hierarchical | sig | Placebo comparison p < 0.15 | — | — | |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hypothesis_test | p_value | Fisher's exact p-value | — | — | 0.681987289541412 |
| by_soc_pt | statistic | Placebo vs. Low Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | 0.682 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hypothesis_test | p_value | Fisher's exact p-value | — | — | 1 |
| by_soc_pt | statistic | Placebo vs. High Dose | AEBODSYS | CARDIAC DISORDERS | AEDECOD | MYOCARDIAL INFARCTION | hypothesis_test | p_value_fmt | Fisher's exact p-value (formatted) | — | — | >0.99 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | PALPITATIONS | hierarchical | n | n | — | — | 0 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | PALPITATIONS | hierarchical | N | N | — | — | 86 |
| by_soc_pt | TRT01A | Placebo | AEBODSYS | CARDIAC DISORDERS | AEDECOD | PALPITATIONS | hierarchical | p | % | — | — | 0 |
Showing the first 250 of 4826 rows — the full ARD is committed beside the display.
- Schema
- opencsr/ard/v1
- Generated
- 2026-09-02T16:11:28Z
- Spec hash
- sha256:a94b85b6e974ae8cc4f19deacfc41f440b4ec4b68c0c8edcc69ca4d6aea3a0ec
- Display hash
- sha256:0511d99eff8bd1d012504f3c1f2857d6c1f9198a71a166450641e2a19444c556
- ARD file
- outputs/t-ae-incidence/v007/ard.json
- ARD hash
- sha256:091de5139418fc160d23400a54f2b6895a2981c8e71fbca4b478665e4a0d4293
Source datasets
| Dataset | Rows | Package | Hash |
|---|---|---|---|
| adsl | 254 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:b022f78fdd0ade028f6c4e9e7cc5187284a5249f30c16646931a1856d5fff2f6 |
| adae | 1191 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:4ffe4e4c90c8a531e95e4931b601c258ed0b83638d4b346e66635d79e78a7bf1 |
Environment
R 4.3.3 · Darwin 23.6.0 · cards 0.6.1 · cardx 0.2.5 · gtsummary 2.3.0 · gt 1.0.0 · dplyr 1.1.4 · pharmaverseadam 1.1.0 · jsonlite 2.0.0 · yaml 2.3.10 · digest 0.6.37
# ------------------------------------------------------------------------------
# t-ae-incidence — Incidence of Treatment Emergent Adverse Events by Treatment Group
# ------------------------------------------------------------------------------
# Target: Table 14-5.01 of the CDISCPILOT01 clinical study report (27 June 2006),
# sixteen pages. Safety population. For every system organ class and every
# preferred term within it: subjects with at least one event, the percentage of
# the arm, the number of events in brackets, and Fisher's exact test of placebo
# against each active arm. The first row is every event in one line.
#
# This is the report's shape, not the FDA-standard one: t-ae-overview (AET01)
# and t-ae-common (AET02) keep their identifiers and their layouts and are what
# the ICH E3 templates carried before v0.4.0; this display is what the CDISC
# pilot profile places (D0032, #62).
# ------------------------------------------------------------------------------
id: t-ae-incidence
title: "Incidence of Treatment Emergent Adverse Events by Treatment Group"
regulatory_id: AET03
type: table
dataset: adae
analysis_set: safety
denominator: adsl
group:
- TRT01A
total: false
analyses:
- name: any
method: subject_count
custom: ard_incidence_any
reference_arm: Placebo
label: "Any body system"
variable: AEDECOD
filter: "TRTEMFL == 'Y'"
- name: by_soc_pt
method: hierarchical_count
custom: ard_incidence_hierarchy
reference_arm: Placebo
label: "Adverse events by system organ class and preferred term"
hierarchy: [AEBODSYS, AEDECOD]
filter: "TRTEMFL == 'Y'"
id: t-ae-incidence
title: "Incidence of Treatment Emergent Adverse Events by Treatment Group"
study: CDISCPILOT01
population_label: "Safety Analysis Set"
cutoff: "2014-07-01"
source: "Source: adae, adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01."
footnotes:
- "Treatment-emergent events are those flagged TRTEMFL = 'Y' in the study's ADAE: events that start on or after the start of treatment, as the reference report (Table 14-5.01) defines them. Adverse events are coded using MedDRA."
- "Subjects are counted once per system organ class and once per preferred term; percentages are based on the number of subjects in the safety population within each treatment group. The bracketed figure is the total number of times an event was recorded."
- "P-values are Fisher's exact test comparing placebo with each active treatment group on the number of subjects with the event. An asterisk is appended to p-values below 0.15, as in the reference report; a p-value that rounds to 1 prints as >0.99; where neither arm has a subject with the event there is no test and the cell is blank."
- "System organ classes are in alphabetical order; preferred terms within a class are in descending order of high-dose subjects, then alphabetical — the order the reference report prints."
- "Four of the 227 p-values the reference report prints differ from this display at the third decimal, each by one thousandth: vomiting (placebo vs high dose, 0.208 here, 0.209 there), salivary hypersecretion (0.057 here, 0.058 there), application site erythema (0.002 here, 0.003 there) and syncope (placebo vs low dose, 0.057 here, 0.058 there). The subject counts agree; R's exact two-sided test gives 0.2085, 0.0575, 0.0025 and 0.0575, and the 2006 program rounded each up. They are recorded and tracked in quality/data/reference-report-agreement.json."
columns:
order: [Placebo, "Xanomeline Low Dose", "Xanomeline High Dose", "Placebo vs. Low Dose", "Placebo vs. High Dose"]
patterns:
"Placebo vs. Low Dose": pvalue
"Placebo vs. High Dose": pvalue
format:
n_pct_events: "{n} ({p}%) [{events}]"
pvalue: "{p_value_fmt}"
zero_count: "0"
digits:
p: 1
events: 0
rows:
- { analysis: any, label: "ANY BODY SYSTEM", pattern: n_pct_events, indent: 0 }
- analysis: by_soc_pt
type: hierarchical
levels: [AEBODSYS, AEDECOD]
pattern: n_pct_events
sort:
outer: alpha
inner: { by_group: "Xanomeline High Dose" }
variants:
post_text: {}
# The report's in-text Table 12-1: preferred terms reported by at least 5% of
# subjects in any arm, listed flat in title case, an asterisk on an active arm
# whose placebo comparison has p < 0.15.
in_text:
title: "Most Common AE's (5% Subjects in any Treatment Group)"
columns:
order: [Placebo, "Xanomeline Low Dose", "Xanomeline High Dose"]
format:
n_pct_sig: "{n} ({p}%){sig}"
zero_count: "0"
digits:
p: 1
rows:
- analysis: by_soc_pt
type: hierarchical
levels: [AEBODSYS, AEDECOD]
pattern: n_pct_sig
inner_only: true
label_case: title
sort:
outer: alpha
inner: { by_group: "Xanomeline High Dose" }
filter:
min_pct: 5
footnotes:
- "Preferred terms reported by at least 5% of subjects in at least one treatment group, as the reference report's Table 12-1; an asterisk marks an active-arm incidence whose Fisher's exact comparison with placebo has p < 0.15. The full display, by system organ class, is Section 14."
# Custom statistics for the reference report's adverse-event incidence tables —
# Table 14-5.01 (all treatment-emergent events) and Table 14-5.02 (serious
# ones), which share this file through t-sae-incidence's `custom_from`.
#
# Each row of those tables carries, per arm, the subjects with at least one
# event, the percentage of the arm, and in brackets the number of times the
# event was recorded; and, in two final columns, Fisher's exact test of placebo
# against each active arm on the subject incidence. The built-in
# `hierarchical_count` method gives the first two of those; the event count and
# the tests are this file's. The report prints an asterisk beside a p-value
# under 0.15, ">0.99" for one that rounds to 1, and nothing at all where both
# arms have no subjects with the event — there is no test to run.
`%||%` <- function(x, y) if (is.null(x)) y else x
half_up <- function(x, digits) {
scale <- 10^digits
sign(x) * floor(abs(x) * scale * (1 + 2 * .Machine$double.eps) + 0.5) / scale
}
fmt_fisher <- function(p) {
if (is.na(p)) return("")
# the report prints a p-value under 0.0005 as 0.000, one that rounds to 1 as
# >0.99, and drops a trailing zero at the third decimal (0.580 prints as 0.58)
s <- if (p >= 0.995) ">0.99" else formatC(half_up(p, 3), format = "f", digits = 3)
if (s != "0.000" && grepl("0{{content}}quot;, s)) s <- sub("0{{content}}quot;, "", s)
if (p < 0.15) paste0(s, "*") else s
}
arm_levels <- function(denominator, group) {
g <- denominator[[group]]
if (is.factor(g)) levels(g) else sort(unique(as.character(g)))
}
# The per-arm statistics for one set of records (a SOC, a PT, or everything).
incidence_stats <- function(records, denominator, group, arms, id) {
g_den <- as.character(denominator[[group]])
g_rec <- as.character(records[[group]])
lapply(arms, function(a) {
N <- length(unique(denominator[[id]][g_den == a]))
n <- length(unique(records[[id]][g_rec == a]))
list(arm = a, N = N, n = n, p = if (N > 0) n / N else NA_real_, events = sum(g_rec == a))
})
}
# Fisher's exact test of the reference arm against each other arm, on subjects.
fisher_rows <- function(stats, reference) {
ref <- Filter(function(s) s$arm == reference, stats)[[1]]
others <- Filter(function(s) s$arm != reference, stats)
lapply(others, function(s) {
p <- if (ref$n == 0 && s$n == 0) {
NA_real_
} else {
stats::fisher.test(rbind(c(ref$n, s$n), c(ref$N - ref$n, s$N - s$n)))$p.value
}
list(level = paste(reference, "vs.", sub("^Xanomeline ", "", s$arm)), p = p)
})
}
row_block <- function(stats, tests, variable, variable_level, group, group2 = NA_character_, group2_level = NA_character_, context = "hierarchical") {
# `sig` is the report's in-text marker (Table 12-1): an asterisk on an active
# arm whose comparison with placebo has p < 0.15, nothing on placebo itself.
sig_for <- function(arm) {
t <- Filter(function(x) endsWith(x$level, sub("^Xanomeline ", "", arm)), tests)
if (!length(t) || is.na(t[[1]]$p)) "" else if (t[[1]]$p < 0.15) "*" else ""
}
arm_rows <- do.call(rbind, lapply(stats, function(s) {
data.frame(
group1 = group, group1_level = s$arm, group2 = group2, group2_level = group2_level,
variable = variable, variable_level = variable_level, context = context,
stat_name = c("n", "N", "p", "events", "sig"),
stat_label = c("n", "N", "%", "Events", "Placebo comparison p < 0.15"),
warning = NA_character_, error = NA_character_, stringsAsFactors = FALSE
)
}))
arm_rows$stat <- unlist(lapply(stats, function(s) list(s$n, s$N, s$p, s$events, sig_for(s$arm))), recursive = FALSE)
test_rows <- do.call(rbind, lapply(tests, function(t) {
data.frame(
group1 = "statistic", group1_level = t$level, group2 = group2, group2_level = group2_level,
variable = variable, variable_level = variable_level, context = "hypothesis_test",
stat_name = c("p_value", "p_value_fmt"),
stat_label = c("Fisher's exact p-value", "Fisher's exact p-value (formatted)"),
warning = NA_character_, error = NA_character_, stringsAsFactors = FALSE
)
}))
test_rows$stat <- unlist(lapply(tests, function(t) list(t$p, fmt_fisher(t$p))), recursive = FALSE)
rbind(arm_rows, test_rows)
}
#' The "ANY BODY SYSTEM" row: every record in the analysis data
ard_incidence_any <- function(data, spec, denominator) {
group <- spec$group
id <- spec$id %||% "USUBJID"
arms <- arm_levels(denominator, group)
stats <- incidence_stats(data, denominator, group, arms, id)
tests <- fisher_rows(stats, spec$reference_arm %||% arms[[1]])
row_block(stats, tests, variable = "ANY", variable_level = NA_character_, group = group, context = "subject_count")
}
#' One block per system organ class, then one per preferred term within it
ard_incidence_hierarchy <- function(data, spec, denominator) {
group <- spec$group
id <- spec$id %||% "USUBJID"
hier <- spec$hierarchy
arms <- arm_levels(denominator, group)
reference <- spec$reference_arm %||% arms[[1]]
out <- list()
for (soc in sort(unique(as.character(data[[hier[1]]])))) {
in_soc <- data[as.character(data[[hier[1]]]) == soc, , drop = FALSE]
stats <- incidence_stats(in_soc, denominator, group, arms, id)
out[[length(out) + 1]] <- row_block(stats, fisher_rows(stats, reference), hier[1], soc, group)
for (pt in sort(unique(as.character(in_soc[[hier[2]]])))) {
in_pt <- in_soc[as.character(in_soc[[hier[2]]]) == pt, , drop = FALSE]
stats <- incidence_stats(in_pt, denominator, group, arms, id)
out[[length(out) + 1]] <- row_block(stats, fisher_rows(stats, reference), hier[2], pt, group, group2 = hier[1], group2_level = soc)
}
}
do.call(rbind, out)
}
v007current
In-text variant redrawn as the reference report prints it (Tables 11-1, 12-1, 12-4; D0032, #63).
2026-09-02T16:11:28Z · @obotclaw
v006
In-text variant redrawn as the reference report prints it (Tables 11-1, 12-1, 12-4; D0032, #63).
2026-09-02T16:10:29Z · @obotclaw
v005
A p-value of 0.000 keeps its zeros; only a single trailing zero at the third decimal is dropped, as the report prints.
2026-09-02T16:02:56Z · @obotclaw
v004
A trailing zero at the third decimal of a p-value is dropped, as the report prints it; the four p-values the reference rounded a thousandth higher are stated in the footnotes.
2026-09-02T16:01:54Z · @obotclaw
v003
A p-value under 0.0005 prints as 0.000, as the reference report prints it.
2026-09-02T15:56:53Z · @obotclaw
v002
Event counts printed as integers; serious-events terms ordered as the reference serious-events program orders them (descending subjects across groups, then name).
2026-09-02T15:53:49Z · @obotclaw
v001
Table 14-5.01 of the reference report (D0032, #62): subjects, percentages and event counts per system organ class and preferred term, with Fisher exact tests of placebo against each active arm; organ classes alphabetical, terms by high-dose count then name.
2026-09-02T15:52:27Z · @obotclaw
Every iteration is kept: outputs/t-ae-incidence/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.